Month: January 2024

PLEASANTON, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) — Healthcare Triangle, Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the “Company”), a leader in digital transformation solutions including managed services, cloud enablement, cybersecurity, data analytics, and AI data processing for the healthcare and life sciences industries, announced that it will sponsoring and participating at the 2024 MUSE Executive Institute, being held Jan 7th-9th, 2024 at The Resort at Pelican Hill in Newport Beach, California. “We are excited to participate and sponsor this prestigious event,” said Lena Kannappan, Co-founder, Head of Business and Strategic Partnerships for Healthcare Triangle. “The event’s theme ‘Solving Workforce Challenges’, encompasses staffing, productivity, and AI integration, for which Healthcare Triangle specializes and...

Findings published in the American Heart Journal show higher clinical diagnostic yield and lower odds of retesting with Zio long-term continuous monitoring service (LTCM) compared to other LTCM and ambulatory cardiac monitoring (ACM) products LTCM was associated with lower incremental health care utilization and costSAN FRANCISCO, Jan. 05, 2024 (GLOBE NEWSWIRE) — (NASDAQ:IRTC) today announced that the results from the Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events (CAMELOT) study have been published in the American Heart Journal (AHJ). The peer-reviewed manuscript, titled “Comparative Effectiveness and Healthcare Utilization for Ambulatory Cardiac Monitoring (ACM) Strategies in Medicare Beneficiaries,” reveals that the Zio long-term continuous monitoring service (LTCM), which features up to 14 continuous...

In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients Initiated dosing in PIVOT-PO Phase 3 trial for tebipenem HBr in cUTI patients. Entitled to receive $95 million in development milestones, payable over two years, as part of the GSK license agreement Updated preliminary cash balance and cash runway guidance into late 2025 CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset, clinical-stage, biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need, today provided a corporate update highlighting its recent accomplishments and anticipated milestones for 2024. “We look forward to another productive...

CORAL GABLES, Fla., Jan. 05, 2024 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share, for total gross proceeds of $150,000,000, before deducting underwriting discounts and expenses payable by Catalyst. Catalyst has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts. The offering is expected to close on or about January 9, 2024, subject to customary closing conditions. All of the shares in the offering are being sold by Catalyst. BofA Securities, Citigroup, Piper Sandler & Co., Cantor,...

Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC; expect to initiate expansion in Q2 2024 and announce initial clinical data in mid-2024 Phase 1 clinical trial of XMT-2056, Immunosynthen HER2 ADC, restarting; plan to advance dose escalation in 2024 Expect capital resources will support current operating plan commitments into 2026 Company to webcast presentation from 42nd Annual J.P. Morgan Healthcare Conference at 2:15 p.m. Eastern Time (ET)/11:15 a.m. Pacific Time (PT) on January 11, 2024CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical...

CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer, effective January 17, 2024. A seasoned financial executive with over twenty years’ experience in the biotechnology industry, Dr. Reine will be responsible for the company’s financing strategy and investor relations, and will oversee all financial operations as Prime Medicine begins its transition into a clinical company. “I am delighted to welcome Allan to Prime Medicine. He brings tremendous financial, operational and leadership experience in the life sciences space, as well as a proven track record developing and implementing multi-pronged...

Acquisition Expected to Contribute More than $8 Million of Annualized Revenue and Positive Net Income MIAMI, Jan. 05, 2024 (GLOBE NEWSWIRE) — Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a high growth global leader in the Health & Wellness sector marketing and manufacturing nutritional foods and supplements worldwide, today announced that it has completed the audit for the planned acquisition of a premier eCommerce nutraceuticals company with operations in North America. The acquisition is expected to close within the next several weeks and is subject to financing and customary closing conditions. “We have now completed the audit for our acquisition and expect to close in early 2024,” stated Darren Minton, CEO of Smart for Life. “Once closed, this will be one of our largest acquisitions since going...

Vancouver, Canada, Jan. 05, 2024 (GLOBE NEWSWIRE) —  WestKam Gold Corp. (TSX-V:WKG)(the “Company” or “WestKam”) wishes to advise that the acquisition of the McConnell Property in British Columbia has been terminated. Under the terms of the definitive agreement (see prior news releases dated December 11, 2023 and July 24, 2023), the Company had until December 31, 2023 to meet all conditions precedent unless an extension was mutually agreed upon by all parties. The terms of the agreement required TSV-V approval of the transaction which included a concurrent financing, as well as issuance of a number of common shares that would result in the vendor holding a 19.99% interest in the Company as of the closing date after giving effect to the issuance of these shares. The parties to the agreement were unable to conclude negotiations on...